April 3, 2008 . A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .
Researchers at the University of Sunderland’s Pharmacy School, Professor Paul Groundwater and Dr. Roz Anderson, in collaboration with Prof. John Perry of Freeman Hospital in Newcastle, Prof. Arthur James of Northumbria University and Sylvain Orenga of bioMérieux have discovered a new technique for the highly specific detection of Pseudomonas aeruginosa, which primarily infects the lungs of patients with cystic fibrosis. It is also a major cause of infection among patients with immune deficiencies, such as patients with AIDS and cancer or those suffering from burns... bioMérieux's Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
April
(50)
- NuRx Pharmaceuticals : Phase I Clinical Trial of F...
- Replidyne Discontinues Phase III Trial
- InterMune : Progress on Pirfenidone in Idiopathic ...
- MedImmune and Infinity : Preclinical Data Highlig...
- Diffusion Pharmaceuticals : patent no. 7,351,844 e...
- Micromet : Phase 1 Clinical Trial with MT110, the ...
- Sorin : approval to market heart-lung machine in J...
- Gene Express : licensing agreement with University...
- Genentech : "AVAiL" Phase III Study of Avastin Plu...
- Spectrum Pharmaceuticals : Preclinical Data Demons...
- Kosan : Phase 2 Trial of Epothilone KOS-1584 in No...
- Infinity Pharmaceuticals' Hedgehog Antagonist Dela...
- Oncolytics Biotech : Dose Escalation in Combinatio...
- Alfacell's ONCONASE : Potential as Radiation Sensi...
- Lilly's ALIMTA : European Approval for Histologica...
- Rosetta Genomics : Agreement With West Coast CLIA ...
- Pharmaxis : CF Trial in Children Returns Positive ...
- MedImmune : Asthma Program with Start of a Phase 2...
- Transave : Study Confirms Anti-Infective ARIKACE E...
- Antisoma and Novartis : phase III lung cancer tria...
- UCB : Phase II results for CDP791 in non-small cel...
- Dinamika : A New Asthma Treatment Introduced by Ru...
- SkyePharma : exclusive License Agreement with Kyor...
- eResearchTechnology, Inc. and nSpire Health, Inc. ...
- Alnylam : ALN-RSV01 in Adult Lung Transplant Pati...
- Critical Therapeutics : Phase I Clinical Trial of ...
- bioMerieux & University of Sunderland : Collaborat...
- TaiGen : Positive Data From the Phase II Study of ...
- Aeolus Pharmaceuticals : AEOL 10150 Protects Lungs...
- AVEO’s Novel Triple VEGF Receptor Inhibitor... Cli...
- Idera Pharmaceuticals : Preclinical Data of its To...
- Kamada : New Orphan Drug Designation by the FDA, f...
- Yale and Asuragen : a microRNA Can Reduce Lung Can...
- Aradigm : Trial of Lung Rx's Inhaled Treprostinil
- KaloBios : Phase 1/2 Trial of Humaneered Monoclona...
- Kamada : Phase III Clinical Trial with Intravenous...
- Cortex : Enrollment in Opiate Induced Respiratory ...
- Actelion and Nippon Shinyaku : pulmonary arterial ...
- Angeion : Medical Graphics Platinum Elite Series P...
- Ceragenix Pharmaceuticals : CeraShield(TM) Coated ...
- NIR Diagnostics : agreement with a European medic...
- Third Wave’s InPlex CF Molecular Test : FDA Clearance
- Celgene : Amrubicin Receives FDA Orphan Drug Desig...
- Lorus : initiation of IND-enabling toxicology stud...
- Poniard Pharmaceuticals : Commercial Manufacturing...
- OXiGENE : Phase II NSCLC Trial of ZYBRESTAT(TM) in...
- Discovery Labs and Chrysalis Technologies : about ...
- MediciNova : Phase II Clinical Trial of MN-221 in ...
- Vertex : Positive Results for VX-770, an Oral Inve...
- Philips : completion of Respironics acquisition
-
▼
April
(50)